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Abstract
Background
In the context of early vaccine trials aimed at evaluating the safety profile of novel vaccines,
abnormal haematological values, such as neutropenia, are often reported. It is therefore
important to evaluate how these trials should be planned not to miss potentially important
safety signals, but also to understand the implications and the clinical relevance.
Methodology
We report and discuss the results from five clinical trials (two with a new Shigella vaccine in
the early stage of clinical development and three with licensed vaccines) where the absolute
neutrophil counts (ANC) were evaluated before and after vaccination. Additionally, we have
performed a systematic review of the literature on cases of neutropenia reported during vac-
cine trials to discuss our results in a more general context.
Principal Findings
Both in our clinical trials and in the literature review, several cases of neutropenia have
been reported, in the first two weeks after vaccination. However, neutropenia was generally
transient and had a benign clinical outcome, after vaccination with either multiple novel can-
didates or well-known licensed vaccines. Additionally, the vaccine recipients with neutrope-
nia frequently had lower baseline ANC than non-neutropenic vaccinees. In many instances
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Conclusions
It is important to include ANC and other haematological tests in early vaccine trials to iden-
tify potential safety signals. Post-vaccination neutropenia is not uncommon, generally tran-
sient and clinically benign, but many vaccine trials do not have a sampling schedule that
allows its detection. Given ethnic variability in the level of circulating neutrophils, normal
ranges taking into account ethnicity should be used for determination of trial inclusion/exclu-
sion criteria and classification of neutropenia related adverse events.
Trial registration
ClinicalTrials.gov NCT02017899, NCT02034500, NCT01771367, NCT01765413,
NCT02523287
Introduction
Understanding vaccine safety requires a comprehensive assessment of all events that occur
after the administration of a vaccine. Adverse events following immunization are defined as
any untoward medical occurrence which follows vaccine administration and which does not
necessarily have a causal relationship with the usage of the vaccine. Characterization of a vac-
cine’s safety profile takes place throughout its development and during its entire life cycle fol-
lowing the first marketing authorization. As vaccines are usually administered to healthy
individuals, the opportunity to collect data on adverse events characterized by laboratory
anomalies is usually confined to the clinical development period when laboratory samples can
be collected in a protocol-specific manner from study participants.
A previous example where an adverse event, identified by an abnormality in a laboratory
parameter, has been associated with administration of a vaccine, is idiopathic thrombocytope-
nic purpura, linked to the administration of measles-containing vaccines. The identification of
this association required several retrospective observational studies analyzing data from mil-
lions of young children over the past two decades [1, 2]. Therefore, it is important to collect
reactogenicity data that would potentially signal a safety concern, early in development as it
allows a more accurate characterization of benefit-risk and ensures that patients and trial sub-
jects are protected. A clear understanding of the potential risks early on will allow for more
comprehensive assessments prospectively following licensure and will provide more informa-
tion to be availed to the public thus increasing trust in the vaccination program.
The aim of this manuscript is to discuss the implications on the design of early phase vac-
cine trials with regard to subject recruitment, screening and post-vaccination follow-up of
enrolled subjects for identifying adverse events characterized by abnormal hematological val-
ues, such as abnormally low neutrophil counts (i.e., neutropenia). Neutropenia is normally
caused by several conditions including infections, drug treatments, autoimmune diseases,
nutritional deficiencies, hematological malignancies, but also by genetic conditions like the
benign ethnic neutropenia (BEN). This latter condition, which affects particularly populations
of African descent and is considered to be due to a regulatory variant in the Duffy antigen
receptor for chemokines gene is not associated with an increased incidence of infection [3–8].
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Additionally, we would like to discuss how post registration clinical trials can be useful in iden-
tifying, for licensed vaccines, potential biomarkers of reactogenicity, including hematological
abnormalities and how these trials can help to put in the right perspective similar findings
from early clinical trials with novel vaccines. Finally, we would like to highlight the clinical rele-
vance and the implications of cases of neutropenia temporally associated with vaccination in
otherwise healthy individuals. The first section of this article includes a description of neutro-
phil counts and their kinetics following administration of both a novel candidate vaccine
against Shigella in two phase I trials and of well-known licensed vaccines in three post-registra-
tion clinical trials. The second section includes a review of publications relating to vaccine clini-
cal trials where neutropenia was noted as an adverse event following immunization.
Materials and Methods
Clinical Studies with the GVGHGMMA Vaccine against Shigella sonnei
Two phase I randomized, placebo controlled, dose-escalation trials assessing safety and immu-
nogenicity of a new vaccine against Shigella sonnei (1790GAHB), developed by the GSK Vac-
cines Institute for Global Health (GVGH) using the Generalized Modules for Membrane
Antigens (GMMA) technology [9], were conducted in healthy European adults aged 18 to 45
years in the context of EC funded FP7 projects STOPENTERICS (http://stopenterics.bio-med.
ch/cms/default.aspx) and ADITEC (http://www.aditecproject.eu/), respectively. Trial 1
(H03_01TP, registered in ClinicalTrials.gov as NCT02017899 and ethically approved by the
“Comité de Protection des Personnes (CPP) Ile de France III”, reference: 2013-0026227-42)
was conducted in France and used three intramuscular (IM) vaccine administrations (given
one month apart) to induce systemic immunity testing 5 different doses (1, 5, 25, 50, 100 μg of
GMMA protein). Trial 2 (H03_02TP, registered as NCT02034500 and ethically approved by
UK National Research Ethics Service (NRES) London—Surrey Borders Committee, reference:
13/LO/1633) was conducted in the UK, used the same schedule and tested three doses (0.1, 1,
10 μg of GMMA protein) by intradermal (ID) route and three doses (5, 20, 80 μg of GMMA
protein) by intranasal (IN) route to induce systemic and mucosal immunity and, as a link to
trial 1, included also a group receiving three intramuscular vaccine administrations with 5 μg/
dose (Fig 1). The vaccine was adsorbed onto 0.35 mg, 0.035 mg and 0.28 mg of Al3+, as Alhy-
drogel, per each IM, ID and IN dose, respectively. Same amounts of Alhydrogel in Tris-buff-
ered saline, were used for the respective IM, ID and IN placebo formulations. Overall, in the
two trials, 80 subjects received vaccine and 22 placebo. As part of the safety follow up, per-
formed throughout the trial, hematology, blood chemistry and urinalysis tests were performed
at different time points before and after each vaccine administration. According to the study
protocol for both trials, safety blood samples were obtained before and 7 days after the first
dose and 28 days after the second and the third dose. Clinically significant changes of labora-
tory test results were defined by investigators based on medical judgment, interpretation of
deviations from respective institution’s normal values and recommendations from the Center
for Biologics Evaluation and Research (CBER) FDA guidance for industry [10]. According to
this note for guidance, decreases in absolute neutrophil counts (ANC) are coded as grade 1 to
grade 4 (Table 1).
Subsequent to 2 episodes of grade 3 neutropenia following the first dose of vaccine (one in
each of the 2 trials) the sponsor and investigators, in consultation with the Data Safety Moni-
toring Board (DSMB), and ethical and regulatory authorities for the two trials, implemented a
more conservative approach for follow-up of study subjects, including collection of blood sam-
ples also at 7 days after the second and the third dose and at the end of the study (i.e., 6 months
after the last vaccine dose).
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Clinical studies with three different licensed vaccines
As part of a series of clinical studies to identify biomarkers of vaccine reactogenicity, in the EC
funded FP7 project BioVacSafe (http://www.biovacsafe.eu/), healthy adult male and female vol-
unteers were recruited to a single UK clinical site (same site where the 1790GAHB vaccine trial
took place) to receive a single vaccination with the recommended adult dose of the following
licensed vaccines: Agrippal (Novartis Vaccines, seasonal trivalent influenza surface antigen,
inactivated, not adjuvanted, n = 21), Fluad (Novartis Vaccines, seasonal trivalent influenza sur-
face antigen, inactivated, adjuvanted with MF59C.1, n = 20), or Stamaril (Sanofi Pasteur, live,
attenuated yellow fever virus 17 D-204 strain, n = 20). Ethical approvals were obtained from
the UK NRES London—Surrey Borders Committee (reference 12/LO/1871, 13/LO/0044). Par-
ticipants receiving Stamaril were naïve to yellow fever as confirmed by serology and immuniza-
tion history. All participants provided written informed consent prior to enrolment. Studies
were registered on ClinicalTrials.gov (NCT01771367, NCT01765413). The participants had an
overall age range of 18–45 years (median 28, mean 28), and were deemed healthy by virtue of
confirmed medical history, examination and baseline blood tests. They were kept as inpatients
for a day before vaccination, and during the first 5 days post vaccination, with controlled diet,
exercise and sleep routines. Blood samples were taken before, daily for the first seven days and
weekly up to day 28 after vaccination, and analyzed for various safety parameters including
automated Full Blood Count with white cell differential (Fig 2). However, for the purpose of
Fig 1. H03_01TP and H03_02TP study flow charts.
doi:10.1371/journal.pone.0157385.g001
Table 1. Absolute Neutrophil Counts Grading.
grade 1 ANC 1500-2000/mm3
grade 2 ANC 1000-1499/mm3
grade 3 ANC 500-999/mm3
grade 4 ANC <500/mm3
doi:10.1371/journal.pone.0157385.t001
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this paper, we only report data on the absolute neutrophil count on days 0–7 (and 0–7, 14,
21and 28 for Stamaril), with a laboratory lower limit of normal range = 2000/mm3.
In a follow-on clinical study within the BioVacSafe project, 228 healthy adult male and
female volunteers (age range of 18–45 years, median 24, mean 27) were recruited to a single
Belgian clinical site to receive a single vaccination with the adult dose of Fluad (Novartis Vac-
cines, seasonal trivalent influenza surface antigen, inactivated, adjuvanted with MF59C.1). The
study was registered as NCT02523287 and ethically approved by the University of Gent Ethical
Committee– 2014/0733). All visits were made as outpatients on days 0, 1, 7 (n = 114) or 0, 1, 3,
7, 21 (n = 114) (Fig 3). Also for this trial, we only report here data on ANC on days 0, 1, 3, 7,
with a laboratory lower limit of normal range = 1573/mm3.
Literature Review
With the literature review, we sought to determine how many articles accessible via PubMed
and reporting data from phase I and phase II vaccine clinical trials, where hematological testing
is more often made, reported the presence of neutropenia as an adverse event following vacci-
nation. We included only articles relating to phase I and phase II vaccine clinical trials enrolling
otherwise healthy participants and thus excluded trials that enrolled special populations with
underlying health conditions, for example, trials conducted in patients with malignancy. In
order to increase the sensitivity of our search, QUOSA software (Elsevier B.V.) was used to
download and search each of the articles for the key words related to our search.
An initial search of PubMed was performed on 21st August 2014. The search included all
years with the first search string including the terms vaccine in combination with the publica-
tion types (clinical trial phase i or clinical trial phase ii) and the Medical Subject Headings
(MESH) term humans. This returned 1931 articles. To ensure that the primary search term did
not exclude relevant articles, a second search was performed with the alteration to exclude the
Fig 2. CRC305A and CRC305C study flow charts.
doi:10.1371/journal.pone.0157385.g002
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MESH term humans. This returned 12 articles none of which fit the criteria of a phase I or
phase II vaccine trial performed on humans (Table 2).
Of the 1931 articles that were retrieved, we attempted to download all full text publications.
The ability to access full length articles was dependent on the company journal subscription
and the availability of free on line publications. A total of 1653 full length articles were accessi-
ble, while the remaining 278 articles were accessed as abstracts only.
The QUOSA software was used to search through each individual article and apply an
exclusion pattern to eliminate articles that dealt with cancer patients as these would not fit our
inclusion criteria of phase I and phase II vaccine clinical trials performed in otherwise healthy
Fig 3. Ghent trial study flow chart.
doi:10.1371/journal.pone.0157385.g003
Table 2. First PubMed Search Results.
vaccine AND “clinical trial, phase i” [Publication Type] OR“clinical trial phase ii” [Publication Type] AND humans[Mesh Terms] 1931 articles
vaccine AND “clinical trial, phase i” [Publication Type] OR“clinical trial phase ii” [Publication Type] NOT humans[Mesh Terms] 12 articles
doi:10.1371/journal.pone.0157385.t002
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subjects. The exclusion pattern read; NOT (cancer OR neoplasm OR tumor OR carcin OR
metastatic OR melanoma OR lymphoma). This returned 771 articles from the original 1931
publications assessed. Of these, 67 included the key words ‘neutropenia OR neutrophil’ and
30 of these just included the word ‘neutropenia’. All 67 articles were read to search for informa-
tion related to the safety assessment. Of the 30 with the keyword neutropenia, 25 described
safety blood draws with noted neutropenia post vaccination, 2 articles did not describe any
safety blood draws for hematology and 3 articles were not vaccine trials. Of the remaining 37
articles with the word neutrophil but not neutropenia, 5 articles described neutropenia or leu-
kopenia following vaccination, 14 articles described safety blood draws being assessed post vac-
cination with no abnormalities detected, 15 articles did not provide any information on blood
samples for safety post vaccination, and 3 articles were not vaccine trials.
While reviewing one of these 67 articles [11], a reference was found citing another article
[12] that described neutropenia as an adverse event following vaccination in a phase I vaccine
clinical trial. This brought the total number of articles returned by this search string to 31.
In order to look for articles that reported results from clinical trials but were not classified as
such in PubMed, a second search string was used to search for articles on vaccines that referred
to phase I, phase 1, phase II or phase 2 anywhere in the PubMed searchable text, but that were
not classified as ‘clinical trial, phase i’ or ‘clinical trial, phase ii’ publication types, while at the
same time excluding the publication types ‘review’, ‘comment’, and ‘editorial’ (Table 3).
This search returned 1005 articles that were downloaded. The QUOSA software was used to
search through individual articles and apply inclusion criteria to return articles that described
subject enrolment. The search was done for the keywords (volunteer OR subject OR recruit
OR patient). This returned 764 articles, and to these, a similar exclusion pattern as described
above was applied to eliminate articles that dealt with cancer. This left 325 articles, and a fur-
ther search using QUOSA found 13 of these articles contained the keywords neutrophil or
neutropenia. Out of these, 3 articles described phase I or phase II vaccine trials where neutro-
phils were measured post vaccination; 2 of these articles described trials where neutropenia
was detected as an adverse event post vaccination.
The first search string was repeated on 23rd of April 2015 with the intention of finding arti-
cles that may have fit our inclusion criteria and been published after the 21st of August 2014,
using the terms (vaccine AND ("clinical trial, phase i"[Publication Type] OR "clinical trial,
phase ii"[Publication Type])) AND humans[MeSH Terms]. This returned 47 papers which
were downloaded. Of these 45 were available as full length articles. These 47 were searched in
QUOSA for the word “neutropenia” and this returned 5 articles. A review of the full length
articles revealed that two articles reported results from trials of a cancer immunogen and a can-
cer vaccine and were therefore excluded, and one dealt with a phase I trial for a dengue vaccine
candidate during which no cases of neutropenia were reported. These three articles were thus
excluded. The other two articles reported the results of phase I and phase II vaccine trials
where neutropenia was noted as an adverse event and were therefore included.
These two search strings returned a total of 35 articles where neutropenia was noted as an
adverse event following vaccination in phase I and phase II vaccine clinical trials available on
PubMed (Fig 4 and Table 4) These 35 articles were read and data extracted for description of:
the type of vaccine, presence of an adjuvant, the time taken from vaccination to event detection
Table 3. PubMed Search Strings.
Vaccine AND (‘phase 1’OR ‘phase 2’OR
‘phase i’OR ‘phase ii’) AND humans [MeSH
Terms]
NOT ‘clinical trial phase i’ [Publication Type] OR
‘clinical trial phase ii’ [Publication Type]
NOT review [publication Type] comment
[Publication Type] editorial [Publication
Type]
doi:10.1371/journal.pone.0157385.t003
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Fig 4. Literature search flow-chart.
doi:10.1371/journal.pone.0157385.g004
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and the mean day of onset of neutropenia, the mean duration of time to recovery, the mean
baseline absolute neutrophil counts, the mean absolute decline in the neutrophil count, the
grading of the neutropenia, association with host factors such as race, gender, and age, recur-
rence of cases upon re-challenge and complications that may have been noted that were associ-
ated with the neutropenia. Two of the authors (VMK and AS) checked each of the papers
assessed in detail for exclusion or inclusion and for those included, for extracting details of the
type of trial etc.
Table 4. Vaccines AssociatedWith Neutropenia Cases in Articles Selected in the Literature Search.
Article’s author Antigen/Pathogen Type of Vaccine Adjuvant Reference ]
Durbin AP, et al. DEN1Δ30 / Dengue 1 Live attenuated None [11]
Morrison D, et al. Tetravalent chimeric / Dengue Live attenuated None [12]
Cunningham CK, et al. GP120 /HIV rProtein Alum/
MF59
[13]
Kotloff KL, et al. Hexavalent rec. peptides /GAS rSubunit Alum [14]
Ellis RD, et al. AMA1/C1/Malaria rProtein Alum+CpG [15]
Duncan CJ, et al. AMA1/C1/Malaria rProtein Alum+CpG [16]
Sheldon EA, et al. rLP2086 / meningococcus B rProtein None [17]
McFarland EJ, et al. vCP1452 / HIV1 rgp120 / HIV1 Viral vectored rProtein None Alum [18]
Dieye TN, et al. MVA 85A / TB Viral Vectored None [19]
Durbin AP, et al. rDEN1Δ30 / Dengue 1 Live attenuated None [20]
Edelman R, et al. Tetravalent / Dengue Live attenuated None [21]
Jaoko W, et al. MVA.HIVA / HIV1 pTHr.HIVA / HIV 1 Viral vectored DNA vectored None None [22]
Karron RA, et Al. H5N1 VN 2004/Aaca / Avian Flu Live attenuated None [23]
Kitchener S, et al. Tetravalent / Dengue Live attenuated None [24]
McArthur JH, et al. rDen4Δ30–200,201; Dengue 4 Live attenuated None [25]
Ouedraogo A, et al. Ad35CS01 / Malaria Viral vectored None [26]
SunW, et al. Tetravalent / Dengue Live attenuated None [27]
Talaat KR, et al. H7N3 / Inﬂuenza Live attenuated None [28]
Chuang I, et al. CS-DNA/AMA-Ad / Malaria DNA prime -Adenovirus boost None [29]
Sedegah M, et al. NMRC-M3V-Ad-PfCA / Malaria Viral vectored None [30]
Watanaveeradej V,
et al.
Tetravalent / Dengue Live attenuated None [31]
Chang LJ, et al. E1, E2, and capsid proteins /Chikungunya virus-like particle None [32]
Njuguna IN, et al. MVA.HIVA Recombinant non replicating
virus
None [33]
Durbin AP, et al. rWN/DEN4Δ30 / Dengue Live attenuated None [34]
SunW, et al. Monovalent (1–4) & Tetravalent / dengue Live attenuated None [35]
Capeding RZ, et al. Tetravalent / Dengue Live attenuated None [36]
Durbin AP, et al. rDEN2/4Δ30 / Dengue 2 Live attenuated None [37]
Vardas E, et al. tgAAC09- HIV1 Viral vectored None [38]
Kanesa-thasan N, et al. ALVAC / Japanese Encephalitis NYVAC / Japanese
Encephalitis
Viral vectored Viral vectored None None [39]
Gershon AA, et al. Varicella-Zoster Oka virus Live attenuated None [40]
Lindow JC, et al. DEN1Δ30;DEN2/4Δ30; DEN3Δ30/31 Live attenuated None [41]
Siberry GK, et al. Men A, C, Y and W-135-DT Conjugate None [42]
Siberry GK, et al. Men A, C, Y and W-135-DT Conjugate None [43]
Wright PF, et al. LGT/DEN4- Tick Borne Encephalitis Live attenuated None [44]
Sanchez V, et al. VDV3 / Dengue Live attenuated None [45]
doi:10.1371/journal.pone.0157385.t004
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Results
Neutrophil count kinetics in the Shigella vaccine trials
Overall, data from the two phase I trials with the GVGH GMMA Shigella vaccine indicate a
good safety profile even at doses as high as 100 μg (i.e. 4-fold higher than Outer Membrane
Vesicles dose in licensed vaccines) by IM route, 80 μg by IN route and 10 μg by ID route. Only
one case of moderate fever was observed in H03_01TP and two in H03_02TP. In this manu-
script we discuss results relating to neutrophil counts in the above studies.
As shown in Fig 5, several instances of ANC values below 2000/mm3 occurred both in the
vaccine and in the placebo groups of the two trials. It should be noted though that the lower
limit of the normal range at the two sites was different (1700/mm3 in France, H03_01TP study,
Fig 5. Absolute neutrophil count at different time points after vaccination with three doses of either
1790GAHB or placebo at 0, 1, and 2 months. (A) H03_01TP study. (B) H03_02TP study. Red dots indicate
subjects who had an absolute neutrophil count less than laboratory normal range on at least one time point
after vaccination. Baseline data are collected during the screening of volunteers. Bars indicate median and
interquartile range. At each time point, dots relating to ANC in vaccinees are on the left hand side and dots
relating to ANC in placebo recipients are on the right hand side.
doi:10.1371/journal.pone.0157385.g005
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and 2000/mm3 in the UK, H03_02TP study). Altogether, in the two trials, we have seen 2 cases
of grade 3 neutropenia (one in each trial) and 6 cases of grade 2 neutropenia (1 case in
H03_01TP and 5 cases in H03_02TP). All cases of grade 2 and grade 3 neutropenia were
reported in vaccinees (N = 80) but not in placebo recipients (N = 22). Baseline median ANC in
vaccinated subjects with cases of neutropenia below 1500/mm3 at any time during the trial was
2200/mm3 and was significantly lower (p = 0.0026, Mann-Whitney Test) than that in vacci-
nated subjects showing no neutropenia below 1500/mm3 throughout the study (i.e., 3355/
mm3).
The two cases of CBER grade 3 neutropenia were reported at day 7 after the first vaccination
with either 50 μg vaccine by IM (H03_01TP) or 20 μg vaccine by IN (H03_02TP) (Table 5).
Both subjects were of African descent, were clinically well at the time of the observation and
did not show any clinically significant local or systemic reaction after vaccination. An addi-
tional blood draw, obtained on day 20 and on day 14 showed an ANC of 1360/mm3 and of
2600/mm3 compared to 880/mm3 and 900/mm3 at day 7, respectively (Table 5). These two
events were classified by investigators of both trials as severe adverse events, but in the absence
of any seriousness criteria they were not considered Serious Adverse Events (SAE).
Of the 6 cases of grade 2 neutropenia, 3 occurred in subjects of African descent and 3 in
Caucasians. Two of these subjects had one episode of neutropenia either at 1 month or at 6
months after the last vaccination while all previous results were within the normal range.
Another of these subjects was already neutropenic at baseline (i.e., 980/mm3) and had a value
of 1260/mm3 after the first dose. Overall in the two trials, 10 subjects were of African descent
and their baseline median ANC (i.e., 2200/mm3) was significantly lower (Mann-Whitney
p = 0.0007) compared to that of the 92 subjects who were not of African descent (i.e., 3555/
mm3).
The cases of neutropenia were thoroughly discussed with investigators and the sponsor’s
pharmacovigilance group, enrollment of new subjects was postponed, and study DSMB asked
for assessment. On a cautionary basis, the DSMB recommended obtaining additional blood
samples to monitor the ANC after vaccination and administration of additional vaccine doses
only to subjects with ANC1800/mm3 (i.e., the WHO threshold for neutropenia). Finally,
they recommended discontinuation from any further vaccination in case of ANC<500/mm3
(i.e., grade 4 AE). These recommendations were endorsed by the sponsor and the respective
ethical and regulatory authorities.
Neutrophil counts in trials with licensed vaccines
As shown in Fig 6, absolute neutropenia was not uncommon after immunization with live,
adjuvanted and unadjuvanted licensed vaccines, but was generally mild (grade 1 and 2) and
Table 5. Grade 3 Cases of Neutropenia Occurred in two Trials After Administration of the First Dose
of the Shigella GMMA Vaccine.
Case 1 (H03_01TP study) Case 2 (H03_02TP study)
Group 50 μg/IM route 20 μg/IN route
Age (yrs) 37 21
Gender Female Female
Ethnicity Black/African descent Black/African descent
Neutrophils count
@ day-21: 2330/mm3 @ day-14: 1800/mm3
@ day 7: 880/mm3 (grade 3) @ day 7: 900/mm3 (grade 3)
@ day 20: 1360/mm3 (grade 2) @ day 14: 2600 /mm3
doi:10.1371/journal.pone.0157385.t005
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always asymptomatic. Participants with post-immunization neutropenia frequently had low
pre-immunization counts or were at or below the interquartile range lower bounds prior to
immunization—especially in the studies where participants were kept as inpatients and under
controlled conditions.
Literature review
The candidate vaccines, associated with neutropenia in the selected papers, included 14 live
attenuated virus vaccines, 6 recombinant protein and peptide vaccines, 7 viral vectored vac-
cines, 1 conjugate vaccine, 1 DNA prime-Adenovirus boost vaccine, 1 canarypox virus-vec-
tored prime- recombinant protein boost vaccine, 1 DNA vectored vaccine and 1 virus like
particle (VLP) vaccine. Of the recombinant protein and peptide vaccines, 2 were formulated
with aluminum adjuvants [13, 14], 1 with both alum and CPG, a synthetic oligodeoxynucleo-
tide that acts as a TLR 9 agonist, [15, 16], 1 with MF59 [13], an oil in water adjuvant, and 1 was
administered without an adjuvant [17]. A recombinant protein administered as a boost follow-
ing priming with a virus vectored vaccine was also administered with an alum adjuvant [18].
Of all these vaccine candidates containing adjuvants, neutropenia and leukopenia were only
Fig 6. Absolute neutrophil count at different time points after vaccination on day 0. (A & B) adjuvanted seasonal TIV. (C)
seasonal TIV. (D) attenuated live yellow fever vaccine. (A, C & D) conducted as inpatients. (B) conducted as outpatients. Red dots
indicate subjects who had an absolute neutrophil count less than laboratory normal range on at least one time point after vaccination.
Bars indicate median and interquartile range.
doi:10.1371/journal.pone.0157385.g006
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linked to the TLR 9 agonist CPG, with the authors noting in both articles that a transient drop
in leukocyte counts was expected following administration of this adjuvant and that this was
probably a result of redistribution of white blood cells as a part of the immune response [15]
[16]. More specifically, Ellis et al. noted a decrease in the neutrophil counts in all subjects
receiving the vaccine candidate with the CPG adjuvant [15].
With regard to temporal associations, a total of 19 articles described the time to detection of
neutropenia following vaccine administration [11, 12, 14, 15, 19–33]. This ranged from detec-
tion on the day of vaccine administration (day 0) in one article [31] to detection 4 weeks post
vaccination in 3 articles [14, 22, 32]. The two instances of neutropenia reported at day 0
occurred before vaccination and normalized 2 and 10 days later, respectively [31]. The time to
detection of neutropenia was dependent on the schedule of blood draws defined in the respec-
tive protocols. The majority of reported cases (14 of the 19 articles) were detected in the first 2
weeks after vaccination. The time from diagnosis to resolution of the neutropenia was reported
in 11 articles [11, 14, 19, 23, 25, 28, 30, 31, 34–36]. In four instances the vaccine was not consid-
ered as the cause of neutropenia; more specifically, Dieye et al [19] reported a single case
deemed to be unrelated to the vaccine candidate; Durbin et al [34] noted no statistical differ-
ence between the number of vaccinees and placebo recipients that suffered neutropenia with
one case linked to infection with Influenza B; Kotloff et al [14] and Taalat et al [28] both diag-
nosed benign ethnic neutropenia (BEN) in patients with a history of low neutrophil counts
prior to vaccination. The other 7 articles reported cases of neutropenia that were probably
related to vaccine administration and that resolved between 2 and 21 days after the diagnosis
of neutropenia had been made. In all cases, resolution of neutropenia was achieved without
any complication.
Three articles described the baseline neutrophil counts, for all subject groups, and their
mean absolute decline following vaccine administration. These articles described the safety
profiles of 2 Dengue virus vaccine candidates (one live attenuated against Dengue 1 and one
chimeric against Dengue 2) and were authored by Durbin et al between 2006 and 2011 [11, 20,
37]. All three articles noted that vaccinees developing neutropenia post vaccination had a lower
baseline ANC than vaccinees that did not develop neutropenia, and this difference was statisti-
cally significant. With regard to the vaccine rDEN1Δ30 [11, 20], two trials revealed that vaccine
recipients with a baseline ANC below 3500/mm3 and 3000/mm3 respectively were more likely
than other vaccine recipients to suffer neutropenia post vaccination. As a matter of fact, vacci-
nated volunteers who became neutropenic had a statistically significant lower mean baseline
ANC value (2475/mm3) than those who did not become neutropenic (3675/mm3) and those
who received placebo (3687/mm3). Additionally, there was no difference in the mean absolute
decline in the neutrophil count between vaccinees that developed neutropenia and those that
did not, although this figure was significantly higher for vaccine recipients versus placebo
recipients. Finally, all subjects who developed neutropenia in these trials recovered fully and
receipt of the vaccine was not a statistically significant predictor of neutropenia, although, as
noted by the authors, this was probably due to the small sample size [20]. Njuguna et al [33]
noted a low mean baseline ANC of 1300/mm3 among the infants enrolled into their study.
Although neutropenia was one of the most commonly reported adverse events in this trial,
there was no statistically significant difference in the incidence of neutropenia among vaccinees
versus the control group and no association was made by the authors between the vaccine and
the neutropenia cases.
Severity of the neutropenia was reported in 30 of the 35 articles retrieved by our search.
This was either classified as mild, moderate or severe or graded by number, that is, grade 1 to 4.
The parameters used for classification differed among trials or was not reported, making it dif-
ficult to compare the severity of neutropenia observed across trials. Importantly, none of the
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articles reported any complications associated with the episodes of neutropenia and no cases of
febrile neutropenia were recorded. Two articles reported only severe cases of neutropenia [17,
38]. In one of them, neutropenia was among the most commonly recorded laboratory adverse
event abnormalities, however during their trial, they did not report the number of mild or
moderate cases that they captured and did not report the parameters of their classification.
Only one severe case (360/mm3) was reported in temporal association with an intercurrent epi-
sode of HIV infection acquired by the subject during the study period due to exposure in the
community. (32). As a matter of fact, HIV is commonly associated with cytopenias of all major
blood cell lines, including neutrophils.Ethnicity of subjects suffering from neutropenia follow-
ing immunization was reported in 10 of the 35 articles retrieved by our search. Cunningham
et al [13] noted that infants of African descent had lower absolute neutrophil counts at 6, 18
and 24 months compared to infants with other ethnic backgrounds. A statistically significant
association between ethnicity and neutropenia was reported in this article, with black infants
more likely to develop neutropenia after vaccination. In contrast, although 60% of enrolled par-
ticipants in a Dengue vaccine trial were of African descent [11], there was no statistical associa-
tion between neutropenia and ethnicity despite the fact that a high proportion of vaccinees
(45%) developed neutropenia and an association was noted between this event and the vaccine.
Four articles described cases of subjects of African descent diagnosed to have benign ethnic
neutropenia who developed neutropenia following administration of the vaccine candidates
[14, 28, 29, 39]. One subject continued to have recurrent episodes of neutropenia throughout
the duration of the trial and his condition was noted as ongoing at the end of the trial. None of
these subjects suffered any complications with their conditions.
With regard to patient factors, aside from ethnicity, Kitchener et al [24] described one case
of neutropenia in a lady with irregular menses. Conversely, no association was described with
regard to age or gender of the vaccinees.
Two articles described episodes of neutropenia following re-challenge with a second dose of
the vaccine candidates. Durbin et al [11] noted that following the second dose of the Dengue 1
vaccine, 9% of the vaccinees developed neutropenia compared with 45% of the same vaccinees
who developed neutropenia after the first dose. In addition to this, they classified all the cases
following the second dose as mild compared to 22% of cases after the first dose that were classi-
fied as severe and 13% that were classified as moderate. Ellis et al [15] noted that all subjects
receiving the CPG containing malaria vaccine candidate had a transient decrease in their neu-
trophil count after the first dose and 92% of them were noted to have a similar decline in neu-
trophil counts after the second dose.
Other factors noted to be associated with neutropenia in these vaccine trials included the
use of cotrimoxazole and zidovudine for prophylaxis by infants born to HIV positive women
as reported by Cunningham et al [13]. Edelman et al [21] noted an association between the
level of reactogenicity of the candidate Dengue vaccine and the likelihood of developing neu-
tropenia. Two articles reported cases of neutropenia occurring with viral infections. Watana-
veeradej et al [31] noted two cases of neutropenia associated with dengue viremia, with one of
these cases resulting from a confirmed wild type infection. Durbin and colleagues [34] reported
a case of severe neutropenia associated with an Influenza B infection.
Discussion
A review of published medical literature available on PubMed revealed that neutropenia had
been captured as an adverse event in>30 phase I and II vaccine trials. Factors that were noted
by the investigators to be associated with neutropenia include low baseline neutrophil counts
prior to vaccination, ethnicity- with subjects of African descent being noted to be more likely
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to develop neutropenia, although this finding was not confirmed in one trial [5], use of the
CPG adjuvant, concurrent use of antiretrovirals and antibiotics, concurrent viral infections.
Cases where vaccination was associated with neutropenia were noted to have recurrence of
neutropenia after re-challenge with subsequent doses, although at a lower frequency and sever-
ity compared to the first vaccine administration [11].
Limitations of the literature and potential biases: this study only searched references from
PubMed, which were either classified as phase 1 or Phase 2 publication or contained a descrip-
tion as a phase 1/I/2/II clinical trials in the Medline searchable text (i.e. title, abstract or MESH
headings). Furthermore, only those papers that were available to the authors as full text were
considered. As such, this survey is not a comprehensive listing of all trials where neutropenia
may have occurred and been reported.
On the other hand, the combination of a relatively non-specific first search, followed by full
text searches using the QUOSA software led to many more papers of interest than was possible
using PubMed alone. For example, using “AND neutrop” as a search term with the original
search to 21st August 2015 returned 22 papers. Only 5 of these were included in our final set of
papers and of the 22, there were no papers missed in the original procedure.
There is a significant potential bias in using these data to estimate the frequency with which
neutropenia occurs in vaccine trials since the majority of phase I and phase II vaccine trial
reports we accessed did not report neutrophil counts (704 of the 771 papers in the initial survey
that did not involve cancer studies). Neutropenia was detected in at least one subject in nearly
a half (30 of 67) of the papers identified in this initial survey that did describe neutrophil
counts. This is likely to be an over-estimate of the frequency since in some cases, these studies
may have included neutrophil counts because earlier studies suggested this may have been a
risk factor (e.g. Dengue papers), or there may be studies were neutrophils were measured but
this was not reported in the paper and this is less likely to occur if neutropenia was observed.
Thus we caution use of these data to estimate the actual frequency of neutropenia in Phase 1
and Phase 2 vaccine trials in healthy subjects. Nevertheless, the results from the literature sur-
vey suggest that decrease in neutrophil counts with transient neutropenia is a common post-
vaccination occurrence with a benign clinical outcome. The results from the trials reported in
the current manuscript do confirm that neutropenia occurring after vaccination is normally
transient, clinically asymptomatic and do not reveal any association with age and gender of
vaccinees.
The ability to diagnose neutropenia as an adverse event is heavily dependent on the design
of the clinical trial and the timing of safety blood draws after vaccination. The majority of cases
reported in the literature were detected in the two weeks following vaccination and therefore
clinical trial designs would only detect these events, which are generally asymptomatic, if the
safety blood draws were carried out to coincide with this period.
No standard definition for neutropenia was used in the articles from our literature search
and no standard definition or severity criteria as an adverse event following immunization, has
been defined. In the future, investigators reporting safety results from vaccine trials might ben-
efit from a standard definition, similar to those provided by the Brighton Collaboration for
other adverse events following immunization, to allow for the use of a single severity score and
allow for the comparison of events across trials.
None of the trials reported cases of febrile neutropenia or any complications associated with
neutropenia. A majority of cases recovered without sequelae, with a single patient, diagnosed
with benign ethnic neutropenia, being noted to have an ongoing condition at the end of the
trial [14].
The results from the trials reported in this manuscript, which include clinical testing of a
novel vaccine against Shigellosis, developed with the GMMAmanufacturing technology, but
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also of licensed vaccines with a well-known good safety profile, support the key findings of the
literature review. All reported cases of neutropenia, including the grade 2 and grade 3 cases
associated with the Shigella vaccination and the several cases reported after immunization with
the licensed vaccines were transient and clinically asymptomatic. Additionally, for the Shigella
vaccine, most of the cases occurred in subjects who had low neutrophil counts at baseline and
in subjects of African descent, known to be more likely to have lower absolute neutrophils
counts (i.e., benign ethnic neutropenia) compared to other ethnicities [3–6].
For this latter reason, the use of clinical laboratory reference intervals derived from non-
African populations to evaluate the safety profile of drugs or vaccines in clinical trials per-
formed in Africa or in persons of African descent is suboptimal, excludes potential trial volun-
teers and makes safety assessments less tailored to the population of interest. To address these
limitations and ultimately increase the scientific validity of African clinical trials, efforts have
been made to establish clinical laboratory reference intervals for various hematology, immu-
nology and biochemistry values among healthy African adults, typical of those who might join
a clinical trial [46]. More specifically for ANC, the referenced cross sectional study, conducted
at seven clinical centers in Rwanda, Uganda, Kenya and Zambia, established a consensus Afri-
can study interval of 1000–5300/mm3 compared to a US based interval of 1800–7700 /mm3.
Should the latter interval be used in a clinical trial as an exclusion criterion, approximately 10%
of healthy volunteers of African descent would have to be excluded from the trial.
As suggested both by our scientific literature search and by the results of the clinical trials,
conducted with vaccines under development or already licensed, neutropenia is a common
asymptomatic and clinically benign post vaccination laboratory abnormality. Monitoring neu-
tropenia and other potential abnormalities in the early phases of clinical development of new
vaccines is important for a more complete characterization of the safety profile of these vac-
cines, however, in consideration of reported ethnical diversities, it should be recommended
that whenever local reference intervals, established through validated assays, are available, they
should be used as inclusion/exclusion criteria or as a tool for determination of thresholds to be
adopted for classification of adverse events in a clinical trial.
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